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Abstract
Background: Myostatin (Mstn) is a negative regulator of muscle growth whose inhibition promotes muscle growth
and regeneration. Dystrophin-deficient mdx mice in which myostatin is knocked out or inhibited postnatally have a
less severe phenotype with greater total mass and strength and less fibrosis and fatty replacement of muscles than
mdx mice with wild-type myostatin expression. Dogs with golden retriever muscular dystrophy (GRMD) have
previously been noted to have increased muscle mass and reduced fibrosis after systemic postnatal myostatin
inhibition. Based partly on these results, myostatin inhibitors are in development for use in human muscular
dystrophies. However, persisting concerns regarding the effects of long-term and profound myostatin
inhibition will not be easily or imminently answered in clinical trials.
Methods: To address these concerns, we developed a canine (GRippet) model by crossbreeding dystrophin-
deficient GRMD dogs with Mstn-heterozygous (Mstn+/−) whippets. A total of four GRippets (dystrophic and
Mstn+/−), three GRMD (dystrophic and Mstn wild-type) dogs, and three non-dystrophic controls from two
litters were evaluated.
Results: Myostatin messenger ribonucleic acid (mRNA) and protein levels were downregulated in both GRMD
and GRippet dogs. GRippets had more severe postural changes and larger (more restricted) maximal joint
flexion angles, apparently due to further exaggeration of disproportionate effects on muscle size. Flexors such
as the cranial sartorius were more hypertrophied on magnetic resonance imaging (MRI) in the GRippets, while
extensors, including the quadriceps femoris, underwent greater atrophy. Myostatin protein levels negatively
correlated with relative cranial sartorius muscle cross-sectional area on MRI, supporting a role in disproportionate
muscle size. Activin receptor type IIB (ActRIIB) expression was higher in dystrophic versus control dogs, consistent with
physiologic feedback between myostatin and ActRIIB. However, there was no differential expression between GRMD
and GRippet dogs. Satellite cell exhaustion was not observed in GRippets up to 3 years of age.
(Continued on next page)
* Correspondence: jkornegay@cvm.tamu.edu
1Department of Pathology and Laboratory Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Department of Neurology, University of North Carolina at Chapel Hill,
Chapel Hill, NC 27599, USA
Full list of author information is available at the end of the article
© 2016 Kornegay et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kornegay et al. Skeletal Muscle  (2016) 6:14 
DOI 10.1186/s13395-016-0085-7
(Continued from previous page)
Conclusions: Partial myostatin loss may exaggerate selective muscle hypertrophy or atrophy/hypoplasia in GRMD
dogs and worsen contractures. While muscle imbalance is not a feature of myostatin inhibition in mdx mice, findings
in a larger animal model could translate to human experience with myostatin inhibitors.
Keywords: Muscular dystrophy, Myostatin inhibition, Dogs, Golden retriever muscular dystrophy (GRMD), Whippets,
Muscle hypertrophy, Contractures
Background
Duchenne muscular dystrophy (DMD) affects approxi-
mately 1 in 5000 newborn boys in whom DMD gene mu-
tations lead to progressive degeneration of cardiac and
skeletal muscle [1–4]. One strategy for promoting muscle
regeneration involves inhibiting myostatin (Mstn; growth
and differentiation factor 8 (GDF-8)), a negative regulator
of muscle growth [5–8]. Humans [9], cattle [10], sheep
[11], and dogs [12] with Mstn gene mutations have dra-
matic muscle hypertrophy. Dystrophin-deficient mdx mice
in which myostatin is knocked out (Mstn−/−) [13] or inhib-
ited postnatally [14, 15] also have a less severe phenotype
with greater absolute force and less fibrosis of individual
muscles.
Based on these findings, there has been increasing inter-
est in treatments to inhibit myostatin and thus promote
muscle growth [16, 17]. However, other studies have iden-
tified potential negative consequences to myostatin inhib-
ition in skeletal muscle. Muscle tendons of Mstn−/− mice
are hypocellular and more brittle [18]. There are differen-
tial muscle effects in myostatin-null mice with, for ex-
ample, the fast-twitch predominant extensor digital longus
(EDL) muscle demonstrating reduced specific isometric
force (force normalized by cross-sectional area (CSA)) and
greater eccentric contraction decrement compared to the
slow twitch soleus [19–21]. Elimination of myostatin in
the dy(W) laminin alpha2-deficient murine model of con-
genital muscular dystrophy was associated with increased
pre-weaning mortality, potentially due to reduced fat for-
mation [22], while blockade of myostatin with transgenic
expression of follistatin in the Dyf−/− model of LGMD2B
and Myoshi myopathy exacerbated muscle degeneration
with aging [23]. Additional questions have been raised
about potential exhaustion of the pool of muscle progeni-
tor cells (i.e., satellite cells) undergoing multiple divisions
in the absence of myostatin in muscular dystrophy [24].
While genetically engineered mice have provided an
extremely powerful tool to study the molecular patho-
genesis of disease [25, 26], results do not necessarily ex-
trapolate to humans, presumably due to differences
between murine and human size and physiology [27].
These shortcomings are partially countered with canine
models, which have been used extensively to study dis-
ease pathogenesis and treatment efficacy [28, 29]. This
trend towards the use of dogs as models will likely
accelerate with the recent sequencing of the canine gen-
ome [30]. We, and others, have investigated the potential
therapeutic role of myostatin inhibition in dogs. Adeno-
associated virus (AAV8)-mediated over expression of the
inhibitory myostatin propeptide was shown to enhance
muscle growth in normal dogs [31]. Analogous results
were demonstrated in dystrophin-deficient golden re-
triever muscular dystrophy (GRMD) dogs [32]. After
13 months, treated GRMD dogs had increased muscle
weights, ranging from 49 % (tibialis cranialis) to 27 %
(EDL), and a suggestion of reduced fibrosis by
histochemistry.
To further study the effects of prolonged loss of myos-
tatin in a large animal model of DMD, we developed a
myostatin-deficient GRMD (GRippet) model by cross-
breeding GRMD dogs with Mstn-heterozygous (Mstn+/−)
whippets [12]. GRippet and Mstn+/+ wild-type GRMD
dogs, together with non-dystrophic control littermates,
were assessed with functional tests, magnetic resonance
imaging (MRI), and molecular/pathologic studies.
Methods
Animals
Dogs from a colony at the University of North Carolina
at Chapel Hill (UNC-CH) received care and were
assessed according to principles outlined in the National
Research Council Guide for the Care and Use of Labora-
tory Animals. Studies were approved by the UNC-CH
Institutional Animal Care and Use Committee (IACUC)
through two protocols, UNC IACUC 08-103, Cross
Breeding of Muscular Dystrophy and Myostatin-Null
Dogs, and UNC IACUC 09-351, Standard Operating
Procedures—Canine X-Linked Muscular Dystrophy. In-
dependent of myostatin status, the dystrophic phenotype
was determined based on elevation of serum creatine
kinase (CK) and characteristic clinical signs. Genotype
was confirmed by polymerase chain reaction (PCR) if
CK results were ambiguous (Table 1).
GRMD
All GRMD colonies worldwide have been derived from
the same founder dog [33]. This dog was initially used to
establish a colony at Cornell University [34]. The ori-
ginal dystrophic golden retriever was crossed with other
breeds. Accordingly, GRMD is not a disease of purebred
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golden retriever dogs. We use the term GRMD to refer to
dogs carrying the underlying splice site mutation [35, 36].
GRippets
Whippet dogs homozygous for the myostatin-null al-
lele (Mstn−/−) (so called bully whippets) have gross
enlargement of muscle, while those that are heterozy-
gous (Mstn+/−) have intermediate muscle mass and
are significantly faster than their myostatin wild-type
counterparts [12]. Semen from a sire (Mstn+/−) of
bully whippet dogs (Mstn−/−) was collected for subse-
quent artificial insemination of a GRMD carrier to
produce a first litter. The second litter was produced
by breeding a GRMD male to Speedy, a GRMD/Mstn
+/− carrier from the first litter. A total of 10 dogs
were studied. Buccal swabs from all dogs of the two
litters were analyzed (DDC Veterinary, Fairfield, OH)
to demonstrate the same Mstn gene deletion at nucle-
otides 939 and 940 described previously [12].
Molecular tests
Prior to muscle biopsy and phenotypic tests, dogs were
premedicated with acepromazine maleate (0.02 mg/kg),
butorphanol (0.4 mg/kg), and atropine sulfate (0.04 mg/
kg), masked, and then intubated and maintained with
sevoflurane. Samples from the cranial sartorius (CS),
vastus lateralis (VL), long digital extensor (LDE), and lat-
eral head of the gastrocnemius (LHG) muscles were re-
moved surgically via open biopsy at 8–9 months of age,
snap frozen in isopentane cooled in liquid nitrogen, and
stored at −80 °C.
RNA isolation
Total cellular ribonucleic acid (RNA) was isolated from
frozen skeletal muscle with Tripure reagent (Roche, In-
dianapolis, IN, USA) and DNase treated with deoxyribo-
nucleic acid (DNA)-free kit (Applied Biosystems, Foster
City, CA, USA). The RNA concentrations of the individ-
ual samples were measured using a Nanodrop 2000
spectrophotometer and assessed for quality using a 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA).
Sequencing
The canine myostatin gene was sequenced using primers
that flank the 939–940 bp mutation site:
F:GTGCTGTCGTTACCCTCTAA/R: GAGACATCTTT
GTGGGAGTACAG (840–1040 bp). The 200 bp PCR
product was cloned into plasmid cloning vector PCR2.1
with TA Cloning Kit (Invitrogen, Carlsbad, CA, USA),
plasmid DNA was prepared using QIAprep Spin Mini-
prep Kit (Qiagen, Hilden, Germany), and the plasmid
DNA was sequenced with M13 forward primer. Multiple
colonies from each dog were selected, and the sequenced
plasmids were assessed to demonstrate the 939–940 bp
deletion in heterozygous dogs.
qRT-PCR analysis
Myostatin gene expression in the CS and the VL from
these 10 dogs was reported previously [37]. Gene expres-
sion in these muscles plus the LDE and LHG was
assessed for this current study. Quantitative realtime
RT-PCR (qRT-PCR) primers were designed using Primer
Express 3.0 software (Applied Biosystems, Foster City,
CA, USA) for the normalizer gene hypoxanthine phos-
phoribosyltransferase 1 (HPRT1). The recommended
ABI TaqMan Gene Expression Assay primer pair and
probe were purchased for the canine Mstn gene (Applied
Biosystems; catalog number cf02704228_m1). Samples of
skeletal muscle RNA (100 ng) were reverse transcribed
with oligo-dT and random octamer primers and Super-
script II (Invitrogen). qRT-PCR was performed in dupli-
cate reactions with Taqman Gene Expression PCR
Master Mix on a 7900HT Fast Real-Time PCR System
(Applied Biosystems).
Phenotypic tests
For all procedures, dogs were anesthetized (above) and
tests were performed as previously described [36, 38].
Joint angles
Pelvic limb joint angles were measured at maximal flexion
and extension, with additional calculation of the range of
motion (ROM), using the method of Jaegger et al. [39].
Our group had previously measured tibiotarsal joint
(TTJ) angle in GRMD dogs with a different method
in the context of serial peroneus longus force mea-
surements [40, 41]. We continue to make this meas-
urement to compare results to historical values. For
this original TTJ angle measurement [40, 41], dogs
were placed in dorsal recumbence, with the stifle held
Table 1 GRMD-myostatin status
Dog name Gender GRMD status Myostatin status
Litter 1
Racer Male Normal Normal
Dash Male Affected Heterozygote
Flash Male Affected Normal
Litter 2
Endora Female Carrier Normal
Esmeralda Female Carrier Heterozygote
Samantha Female Affected Normal
Tabitha Female Affected Heterozygote
Hagatha Female Affected Normal
Derwood Male Affected Heterozygote
Abner Male Affected Heterozygote
Kornegay et al. Skeletal Muscle  (2016) 6:14 Page 3 of 17
at a 90° angle and the tibia/fibula positioned parallel
to the table. The angle formed by the flexor surface
of the tarsus was measured using a goniometer cen-
tered over the lateral malleolus of the fibula. Values
for normal dogs using this method approximate but
are somewhat less than those recorded at maximal
extension.
Tibiotarsal joint force and ECD
Force and eccentric contraction decrement (ECD) were
assessed as previously described [38, 42, 43]. Briefly, TTJ
flexion and extension torque was measured using a
rapid-response servomotor/force transducer (model
310B LR, Aurora Scientific, Inc., Aurora, Ontario,
Canada) controlled by a personal computer using cus-
tom LabView software. Supramaximal 150 V, 100-μs
pulses were applied percutaneously (Model S48 Solid
State Square Wave Stimulator, Grass Instruments,
Quincy, MA, USA) in a 1.5-s tetanic run of 75 pulses
(50/s) to the peroneal (flexion) and tibial (extension)
nerves. The site of contact for the paw with the lever
(moment arm) was estimated to be 75 % of the distance
between the point of the hock and the distal digit.
Torque (Newton (N)-meters (m)) was divided by the
moment arm (m) to convert to force (N).
Eccentric contractions were induced by percutaneously
stimulating the peroneal nerve using square wave pulses
of 100-μs duration in a tetanic run for 1 s at a frequency
of 50 Hz while simultaneously extending the TTJ with a
servomotor (Aurora Scientific) [38, 43]. Thus, the mus-
cles of the cranial tibial compartment were repeatedly
stretched to induce mechanical damage. Three sets of 10
stretches for a total of 30, each set separated by 4 min,
were performed. Contraction-induced injury was quanti-
fied by the force (torque) deficit (Fd) using the following
equation: Fd = (Maximal isometric tetanic force [Po] be-
fore stretch − Po after stretch/Po before stretch) × 100.
Cranial sartorius circumference
We have previously shown that the CS muscle under-
goes dramatic hypertrophy in GRMD dogs and that this
hypertrophy tracks with postural abnormalities [44]. Ac-
cordingly, as previously described [38], we used CS cir-
cumference measured at surgery during routine biopsy
as a surrogate for muscle hypertrophy and associated
postural changes in GRMD.
MRI
Studies were done on either a Siemens 3T Allegra Head-
Only MRI scanner using a circular polarization (CP)
head coil or on a whole body MAGNETOM Trio with
Tim system with a 32-channel body coil (composed of a
16 element anterior part and 16 element posterior part)
at the UNC-CH Biomedical Research Imaging Center
[45, 46]. Dogs were placed on an MRI gantry in the ster-
nal (prone) position with the pelvic limbs extended and
scanned using a published protocol [45]. T2-weighted
image sequences with fat saturation (T2fs) and without fat
saturation (T2w) were acquired using a variable-flip-angle
turbo spin echo (TSE) sequence. A multi-spin-echo T2
(MSE-T2), with a ten-echo Carr-Purcell-Meiboom-Gill se-
quence, was acquired to calculate T2 mapping [45, 47].
The T2 mapping was calculated on a voxel-by-voxel basis
for the proximal pelvic limbs of dogs in the transverse
plane of MSE-T2 images by fitting an exponential decay
curve to the signal intensity of the corresponding voxels
using a linear-least-squares curve-fitting algorithm [45].
The major proximal pelvic limb muscles in T2w were
registered and then manually segmented, while T2fs was
used to identify the contour of each muscle. All prox-
imal pelvic limb muscles were segmented but only five
slices at the mid-femur were analyzed/quantified [48].
The T2fs and T2 mapping were subsequently automatic-
ally aligned to the coordinate space of T2w using a rigid
image registration technique [45]. Thus, the muscle seg-
mentation in T2w could be used in T2 mapping for the
biomarker analysis. Texture analysis features were
assessed as potential markers of patchy lesions such as
necrosis [49, 50].
Femur length was used to correct absolute muscle vol-
umes as previously described [46]. To determine overall
scores for T2 and the texture features in each group, the
proportional muscle volume was considered, so as to
calculate a weighted average.
Muscle histochemical and immunoblot studies
Morphometric analysis of muscle was performed in a
blinded fashion. Muscle fibers were aligned for true
cross sections (10 μm), stained with hematoxylin and
eosin (H&E), and viewed with a light microscope (Axio-
cam System, Zeiss; GERMANY) at high power. Numbers
per 100 myofibers were counted for degenerating fibers
(hyaline and/or fragmenting fibers with/without evi-
dence of myophagocytosis), regenerating fibers (small fi-
bers with basophilic nuclei and prominent nuclei/
nucleoli), and centrally nucleated fibers (fibers with nu-
clei located away from the sarcolemma within the cyto-
plasm; CNF). Muscle fiber CSAs were determined using
Scio Image Software (National Institutes of Health
(NIH)). A total of 200–600 fibers were measured for
each muscle of each dog.
Immunoblots of cell lysates and tissue homogenates
were performed as previously described [51]. Hydroxypro-
line (HP) content of various muscles was measured using
a modification of Woessner and colleagues [52] as
described [51]. Values are expressed as μg HP/mg of total
muscle protein. For activin receptor type IIB (ActRIIB)
Western blots, frozen muscle samples were homogenized
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in Tissue Extraction Reagent I (Invitrogen), followed by
quantification with the BCA Protein Assay Kit (Thermo-
Fisher Scientific, Grand Island, NY, USA). Five micro-
grams (μg) of total protein from each muscle were loaded
onto Novex 10 % Tris-Glycine gels and transferred to
polyvinylidene difluoride (PVDF) membranes. Antibodies
used were ActRIIB (Abcam ab76940; Cambridge, MA,
USA), at a concentration of 1:500, and secondary en-
hanced chemilumescent (ECL)-anti-mouse IgG, 1:5,000
(GE Healthcare NA931V; Pittsburgh, PA, USA). Following
visualization with the Amersham ECL Prime Western
Blotting Detection Reagent (GE Healthcare), quantifica-
tion was performed using the NIH ImageJ program.
Myostatin (GDF-8) levels from the tissue lysates were de-
termined using an immunoaffinity liquid chromatography-
mass spectrometry (LC-MS) workflow. Tissue lysates were
prepared by homogenization of each muscle sample using
tissue protein extraction reagent (TPER, Pierce cat 78510)
(ThermoFisher Scientific). Homogenate was centrifuged
and 20 μL of the supernatant was used for myostatin ana-
lysis. Quantification of myostatin was performed against
recombinantly produced myostatin protein (R&D Systems,
Inc. Minneapolis, MN, USA; catalog number 788-G8). Re-
combinant protein standards were prepared in 1 % bovine
serum albumin (BSA) in phosphate buffered saline contain-
ing 0.05 % Tween-20 (PBST). A seven-point standard curve
was prepared from 0.1 to 12.8 ng/mL by serial dilution. Tis-
sue levels were back calculated against this standard curve
and normalized using tissue weight; levels are reported in
pg of myostatin per mg of tissue. Samples were prepared by
first adding 200 μL of 0.1 M Glycine buffer (pH 2.5) to
20 μL of sample and incubating for 1 h at room
temperature. After 1 h, 50 μL of 1 M tris buffer (pH 8) was
added to each sample, followed by 1 μg of biotin conju-
gated anti-GDF-8 antibody and incubated overnight at 4 °
C. After incubation, streptavidin magnetic beads were used
to isolate the myostatin/antibody complex. The magnetic
beads were washed twice with PBST, followed by one PBS
wash. Myostatin was then separated from the antibody and
beads using 140 μL of 30 mM hydrochloric acid prepared
in water. The acid eluate was then neutralized using 30 μL
of 1 M tris buffer (pH 8). All samples were subsequently
reduced using dithiothreitol (DTT), cysteines were alky-
lated with iodoacetamide, and the protein was digested
using trypsin. Quantification occurred by nano liquid
chromatography-mass spectrometry and liquid chromatog-
raphy (LC-MS-MS) using an API 5500Q mass spectrom-
eter against the tryptic peptide IPAMVVDR.
Satellite cell quantitation
For satellite cell quantification of muscle, Tabitha,
Hagatha, Endora, and Esmerelda were anesthetized at
37 months of age and samples of the CS and VL were
removed surgically and processed as described above.
Muscle cryosections (10 μm) were immunostained using
antibodies to Pax7 (Developmental Studies Hybridoma
Bank (DSHB), Iowa City, IA; 1:10) followed by goat anti-
mouse secondary antibody (Alexa Fluor 488, Invitrogen
A11001; 1:500) and an antibody to laminin (2E8, DSHB,
1:100), and then goat anti-rabbit secondary antibody
(Alexa Fluor 594, Invitrogen, A11012; 1:500). All nuclei
were labeled with 4′,6-diamidino-2-phenylindole (DAPI)
in mounting medium (P36930, Invitrogen). Image cap-
ture was performed using an upright microscope for
bright field, differential interference contrast (DIC), and
epifluorescence with an ApoTome structured illumin-
ation digital imaging system (Carl Zeiss Meditec, Inc,
Dublin, CA). The image stacks consisted of six optical
sections with 1.4 mm Z-steps. Nuclei staining positive
for DAPI but outside laminin extracellular membranes
were considered interstitial cells, while those inside lam-
inin were considered myonuclei. Satellite cells were
identified as Paired Box 7 (Pax7)+ nuclei within laminin
staining as shown in Additional file 1: Figure S1 and as
previously described [53].
Statistical analysis
The statistical package, R version 3.0.1 [54], was used for
all statistical analyses. Analysis of variance (ANOVA)
tests were used to compare results from individual dys-
trophic groups and controls. From the ANOVA tests, we
examined whether at least one group was significantly
different from the others. Once the null hypothesis was
rejected in the ANOVA, we performed a post hoc
Tukey’s honest significant differences (HSD) test to iden-
tify differences between a pair of groups. The model can
be written as yij = μi + Εij, where the subscript i repre-
sents the group (1 =GRippets; 2 = GRMD dogs; 3 = non-
dystrophic controls), the subscript j represents the jth
subject, the yij is the response variable of the jth subject
of the ith group, the μi is the mean of the ith group, and
the error term Εij is assumed to have a standard normal
distribution. This model was repeated to assess messen-
ger ribonucleic acid (mRNA) and protein data, plus each
MRI marker, texture feature, functional measurement,
and histopathological lesion of each muscle. We com-
puted Pearson correlation coefficients between MRI,
histopathological, and mRNA/protein data. To account
for multiple comparisons, we applied the false discovery
rate (FDR) method to calculate the corrected p values
[55]. A value of p < 0.05 was considered significant.
Trends were cited if p < 0.2.
Results
Key molecular and phenotypic features of the dogs of
this study are discussed below. Data are expressed as
mean ± SD. Because of the small group sizes and strin-
gency of the FDR statistical method, many of the
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differences between the two dystrophic groups did not
reach significance. Significant (p < 0.05) findings and
those that trended towards significance (p < 0.2) between
GRMD and GRippet dogs are summarized in Table 2;
some are illustrated in Fig. 1.
Posture, gait, and outcome
Objective measures of gait, such as accelerometry and
video gait analysis, were not evaluated in these dogs.
However, key postural changes and quantitative joint
angle measurements (below) were compared between
the two dystrophic groups. Overall, the dystrophic
dogs had a more plantigrade posture and gait, with
the limbs shifted forward under the torso. A planti-
grade posture results from the carpi being hyperex-
tended (dorsal flexion) and the tarsi being hyperflexed
(palmar flexion). Postural abnormalities were more
pronounced in the GRippets, equating to a more se-
vere GRMD phenotype. These changes varied between
the two litters. Dash (GRippet) from the first litter
had a pronounced plantigrade stance, and his pelvic
limbs were shifted forward (Fig. 2). He was no longer
ambulatory at 9 months of age and was euthanized.
Similar but milder postural changes were seen in the
three GRippets of the second litter (Derwood, Abner,
and Tabitha) (Fig. 3). While these dogs retained the
ability to walk, they developed glossal hypertrophy,
which interfered with their ability to eat (Fig. 4).
Resulting weight loss necessitated euthanasia of Abner
and Derwood at 9 and 11 months, respectively. The
final GRippet, Tabitha, remained ambulatory but had
pronounced postural abnormalities and was eutha-
nized at 41 months.
Joint angles
Compared to control dogs, joint angles of GRMD dogs
were similar, whereas those of GRippets differed. The
GRippet hip angle with maximal flexion was larger
(more restricted) (77.5° ± 4.93), and hip ROM was
smaller (56.5 ± 12.5) versus controls (58.3° ± 5.51, p <
0.01 for flexion; 87.7 ± 15.9, p < 0.05 for ROM) (Fig. 1a).
An unexpected and important finding was that GRippets
had larger (more restricted) maximal TTJ (53.5° ± 7.85),
stifle (42.0 ± 5.35), and hip (77.5° ± 4.93) (Fig. 1a) flexion
angles compared to GRMD dogs (35.0 ± 7.00, 34.0 ±
3.61, and 63.0 ± 3.61, respectively) (p < 0.05 for TTJ and
hip; p = 0.173 for stifle). The TTJ ROM motion trended
towards being significantly decreased in the GRippets
(p = 0.052) (Table 3).
Force and ECD
As with the joint angle data, GRippet body-mass-
corrected force values (N/kg) varied markedly between
the two litters. Dash from the first litter had dramatically
higher TTJ tetanic flexion force (12.5) compared to the
three GRMD dogs from the second litter (6.63 ± 1.59). A
comparable but reversed differential was seen for exten-
sor force, with Dash having a value of 11.1 versus 28.8 ±
2.75 for the other three GRippets. Flexion force values
for GRippet (0.70 ± 0.41) and GRMD dogs (0.59 ± 0.32)
were each lower than the controls (1.54 ± 0.04) (p < 0.05
for both). The GRMD (1.93 ± 0.41) and GRippet (1.92 ±
0.64) dogs also had lower extension force compared to
controls (3.16 ± 0.48) (p < 0.05 for GRippets and p =
0.062 for GRMD). Values for ECD after either 10 or 30
contractions were higher in each dystrophic group ver-
sus controls (p < 0.05 for all). Neither force nor ECD







Maximal hip joint flexion angle (o) 77.5 ± 4.93 63.0 ± 3.61 0.05
Maximal tarsal joint flexion angle (o) 53.5 ± 7.85 35.0 ± 7.0 0.05
Maximal stifle joint flexion angle (o) 42.0 ± 5.35 34.0 ± 3.61 0.173
Tarsal range of motion (o) 104 ± 8.73 123 ± 4.04 0.052
Magnetic resonance imaging
Rectus femoris percent cross-sectional area 2.70 ± 0.76 4.29 ± 0.30 0.168
Quadriceps femoris percent cross-sectional area 15.9 ± 0.61 21.6 ± 0.94 0.162
CS/VL ratio (volume and percent cross-sectional area) 0.86 ± 0.19 0.48 ± 0.04 0.168
Molecular/histopathology
Lateral head gastrocnemius myostatin mRNA fold change 1.35 ± 0.682 0.565 ± 0.454 0.192
Overall average degenerating fibers (%) 2.58 ± 0.36 3.97 ± 1.21 0.082
Cranial sartorius fiber cross-sectional area (mm2) 4,133 ± 233 2,661 ± 316 0.01
Cranial sartorius centrally nucleated fibers (%) 20.7 ± 3.82 11.4 ± 5.23 0.132
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values differed significantly between the two dystrophic
groups (Table 4).
Cranial sartorius circumference
Cranial sartorius circumference corrected for body mass
(mm/kg) trended towards being higher in the GRippets
(5.05 ± 1.72; p = 0.053) but not GRMD dogs (3.39 ± 0.52,
p = 0.617) when compared to controls (2.46 ± 0.25).




Effects of muscle atrophy or hypertrophy in dystrophic
dogs were demonstrated by MRI, with parallel changes
being seen with both absolute (mm3) and femur length-
corrected (mm3/mm) volumes and the percent contribu-
tion that each muscle made to the overall CSA (Fig. 5
and Additional file 1: Figure S1; Additional file 2:
Table S1).
Muscle volumes varied considerably among the dogs
and were not clearly associated with Mstn gene
Fig. 1 Histograms demonstrating differences among control, GRMD, and GRippet dogs. a Maximal hip joint flexion angle. b Quadriceps femoris MRI
percent cross-sectional area. c Cranial sartorius to vastus lateralis MRI percent cross-sectional area ratio. d Cranial sartorius fiber cross-sectional area. For
each of these phenotypic measures, differences between control and dystrophic dogs are more pronounced in the GRippets versus GRMD dogs
Kornegay et al. Skeletal Muscle  (2016) 6:14 Page 7 of 17
status. As an example, overall mid-femur length-
corrected muscle volume in the transverse plane
ranged from 114 in Hagatha (GRMD) to 191 in
Endora (GRMD carrier/Mstn+/+). Racer, the only dog
that was normal for both genetic traits, had an inter-
mediate value of 164. Esmeralda (GRMD normal/
Mstn+/–) had a higher value (173), potentially in keep-
ing with a hypertrophic effect of myostatin loss, but
Endora’s value was even higher (191).
A differential effect of the dystrophy trait on indi-
vidual muscles was demonstrated by assessing vol-
umes of the quadriceps femoris (QF) and the
combined cranial and caudal sartorius (total sartorius)
muscles. The corrected QF volume ranged from 19.2
in Dash (GRippet) to 47.0 for Racer, while an
Fig. 2 Comparative posture and muscle mass of dogs from the first litter. a Left to right, Racer (muscular dystrophy normal; Mstn+/+), Flash (GRMD;
Mstn+/+), and Dash (GRippet; Mstn+/−), illustrating stunting in Flash and Dash and dramatic postural changes in Dash. b Dash (GRippet; Mstn+/−): note
the forward shift and plantigrade positioning of the pelvic limbs. c, d The CS and hamstring muscles (circles) in Dash (c) are relatively hypertrophied
compared to Flash (d)
Fig. 3 Comparative posture of dystrophic dogs from the second
litter. Note the comparative posture of the dystrophic GRMD
(Hagatha) (a) and GRippet (Derwood) (b) dogs. Derwood’s carpal
joints are hyperextended, resulting in a more plantigrade stance
in the thoracic limbs (lines are drawn to delineate the carpal
joint in each dog). Hagatha has a normal upright posture, while
Derwood’s lumbar spine is kyphotic and his thoracic and pelvic
limbs are shifted under the trunk (represented by the shorter
line extending from the elbow to the stifle)
Fig. 4 Glossal hypertrophy in dystrophic GRippet dog. Lateral
view of the pharyngeal area of GRippet dog, Derwood, illustrating
glossal hypertrophy. The tongue extends well ventral to the line
demarcating the mandible and ventral aspect of the oral cavity [76]
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opposite pattern was seen for the total sartorius, with
values ranging from 4.3 for Racer to 13.0 for Dash.
GRippet and GRMD dogs versus non-dystrophic controls
When data from individual dystrophic groups were com-
pared, controls had greater absolute (29,631 ± 274), and
femur length-corrected (178 ± 13.4) volumes than either
GRMD (19,682 ± 1255, absolute; 125 ± 8.87, corrected)
or GRippet (21,791 ± 1409, absolute; 137 ± 7.76, cor-
rected) dystrophic dogs (p < 0.01 for all). Differential
effects on individual muscles paralleled those of the indi-
vidual dogs. Control QF volumes were larger than those
of either dystrophic group (p < 0.01 for both). Total
sartorius volumes of the controls were smaller than
those for either GRippet or GRMD dogs, with the GRip-
pet value trending towards significance (p = 0.159 for
absolute and 0.112 for corrected). In comparing either
absolute or corrected volumes of the other muscles of
the two dystrophic groups separately to controls, only
the biceps femoris differed, being significantly smaller in
both the GRMD and GRippet dogs (p < 0.01 for most).
With regard to CSA, the QF accounted for 25.4 ± 2.99 %
in the controls, versus 21.6 ± 0.9 % in the GRMD dogs and
15.9 ± 0.61 % in the GRippets (Fig. 1b). Values for the GRip-
pets differed significantly from controls (p < 0.01) but those
for the GRMD dogs did not (p = 0.864). The CS/VL ratio
showed a clear progression from the controls (0.24 ± 0.06),
to the GRMD dogs (0.48 ± 0.04), to the GRippets (0.86 ±
0.19) (Fig. 1c), indicating that reduction in myostatin
accentuated unequal muscle growth in dystrophic dogs.
Differences for GRippets versus controls were significant
(p < 0.05), but those for GRMD dogs were not (p = 0.864).
GRippet versus GRMD dogs
While GRippet absolute and femur length-corrected
total muscle volumes were similar to those of the
GRMD dogs, the pattern of differential muscle in-
volvement between dystrophic and control dogs was
exaggerated in the GRippets. For almost all muscles,
the degree of atrophy or hypertrophy in GRMD dogs
was more pronounced in the GRippets (Additional file
1: Figure S1). The differential effects on the quadri-
ceps and sartorius muscles were highlighted by the
CS/VL ratio, which trended towards being higher in
the GRippets (p = 0.168).
Individual muscle volume on MRI and joint angles of
the 10 dogs were correlated to clarify whether imbal-
anced muscle volume/strength contributed to postural
changes. We expected that CS muscle volume would
correlate negatively with TTJ angle measured by our ori-
ginal method [38] but neither the muscle volumes nor
the percent CSA values correlated. This outcome may
have been influenced by the age of the dogs. With our
prior studies, the correlation was noted at 6 months of
age; correlations have not been demonstrated at other
ages. On the other hand, CS and total sartorius absolute
volumes and percent CSA correlated positively with
maximal hip flexion angle (r = 0.671 to 0.756; p < 0.05
for all but CS absolute volume for which p = 0.063).
There was also a strong negative correlation between ab-
solute and femur length-corrected QF volume (r =
−0.829 and 0.809) and percent CSA (r = −0.935) versus
maximal hip flexion (p < 0.05 for absolute and corrected
volumes and 0.01 for percent CSA). These correlations
could be in keeping with biomechanical relationships or
Table 3 Joint angles in non-dystrophic control, GRMD (Mstn+/+), and GRippet (Mstn+/−) dogs
Genotype Tarsal joint (mean ± SD) Stifle joint (mean ± SD) Hip joint (mean ± SD)
Original Flexion Extension ROM Flexion Extension ROM Flexion Extension ROM
Controls 150 ± 11.1 45.0 ± 8.0 153 ± 6.43 108 ± 11.0 39.3 ± 6.03 146 ± 14.0 107 ± 11.4 58.3 ± 5.51b** 146 ± 10.4 87.7 ± 15.9b*
GRMD (Mstn+/+) 153 ± 12.0 35.0 ± 7.0b* 158 ± 11.0 123 ± 4.04 34.0 ± 3.61 138 ± 5.0 104 ± 7.94 63.0 ± 3.61b* 140 ± 10.8 76.7 ± 13.3
GRippet (Mstn+/−) 147 ± 19.4 53.5 ± 7.85a* 157 ± 12.5 104 ± 8.73 42.0 ± 5.35 140 ± 5.26 97.5 ± 6.56 77.5 ± 4.93a* 134 ± 13.3 56.5 ± 12.5
ROM range of motion
aSignificantly different (*p < 0.05) from GRMD dogs
bSignificantly different (*p < 0.05; **p < 0.01) from GRippets
Table 4 Body-mass-corrected tetanic force (N/Kg) and ECD measurements in non-dystrophic control, GRMD (Mstn+/+), and GRippet
(Mstn+/−) dogs
Flexion (mean ± SD) Extension (mean ± SD) ECD (10) (mean ± SD) ECD (30) (mean ± SD)
Controls 1.54 ± 0.04a*,b* 3.16 ± 0.48b* 9.38 ± 6.18a*,b* 22.1 ± 11.6a*,b*
GRMD (Mstn+/+) 0.59 ± 0.32 1.93 ± 0.41 38.6 ± 14.8 64.2 ± 7.56
GRippet (Mstn+/−) 0.70 ± 0.41 1.92 ± 0.64 33.2 ± 2.77 61.7 ± 15.7
ECD percent eccentric contraction decrement after 10 and 30 tetanic flexion contractions
aSignificantly different (*p < 0.05) from GRMD dogs
bSignificantly different (*p < 0.05) from GRippets
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represent independent variables tracking with the dis-
ease phenotype.
T2 mapping values and texture analysis
The overall T2 mapping value for the non-dystrophic con-
trol dogs (38.2 ± 5.00) was lower than that for the GRip-
pets (52.3 ± 3.47) and GRMD dogs (51.9 ± 5.09) (p < 0.05
for both). T2 mapping values of individual muscles, with
the exception of the sartorius heads, were also higher, al-
though differences generally only trended towards signifi-
cance. Values for texture analysis features did not differ
significantly among the three groups (data not shown)
(Additional file 3: Table S2).
Pathologic and molecular findings
Histopathologic changes (degenerating and regenerating
fibers; centrally nucleated fibers)
Averaged scores for degenerating fibers and CNF were
higher in GRippet and GRMD dogs versus controls (p <
0.01 for all but CNF in GRMD which was <0.05). In
contrast, the difference for regenerating fiber scores in
the two dystrophic groups only trended towards signifi-
cance in GRMD dogs (p = 0.101) and was not significant
in the GRippets (p = 0.523). Most scores for degenerating
and regenerating fibers for individual muscles of separ-
ate dystrophic groups did not differ from control indi-
vidual muscles. The one exception was the presence of
greater numbers of degenerating fibers in the LDE of the
GRMD dogs (p < 0.05). In contrast, CNF were increased
in both dystrophic groups compared to controls in all
muscles (p < 0.05 for most). Importantly, histopathologic
lesions in GRippet and GRMD muscle did not differ.
Specifically, there were no statistically significant differ-
ences in degenerating, regenerating, or CNF in GRippets
compared to their GRMD littermates (Additional file 4:
Table S3).
Pax7-positive nuclei
To investigate the potential that modulation of myostatin
in muscular dystrophy might lead to exhaustion of the sat-
ellite cell pool, we quantified Pax7-positive nuclei in two
dystrophic dogs, including one GRippet (Tabitha) and an-
other Mstn+/+ GRMD dog (Hagatha), as well as two
GRMD carriers that differed on myostatin status (Endora
(Mstn+/+) and Esmerelda (Mstn+/−)). All dogs were adults,
37 months of age. There were no statistically significant
differences in satellite cell numbers between muscles from
dogs of different myostatin genotypes. However, some-
what unexpectedly, Pax7-positive cells accounted for a
higher percentage of myonuclei in the two dystrophic
dogs (4.3–5.7 %) versus the two GRMD carriers (0.6–
2.8 %) for the four muscles studied (Table 5; Additional
file 5: Figure S2).
CSA of myofibers
Consistent with the increase in muscle fiber size in the
genetic absence or postnatal blockade of myostatin [6,
14], the CSA for the GRippet CS muscle (4133 ± 233)
was larger than that of their GRMD littermates (2661 ±
316) (p < 0.01). In comparing the CSA of the CS
fibers to controls (2,598 ± 346), GRippets had larger
Fig. 5 Averaged MRI segmentation of dogs from the three groups. Averaged T2-FS MRI images of pelvic limb muscles in the transverse plane at
the level of the midthigh are shown in non-dystrophic control (a) dystrophic GRMD Mstn+/+ (b) and GRippet Mstn+/− (c) dogs. Note the proportional
enlargement of the sartorius and hamstring muscles and the associated atrophy/hypoplasia of the quadriceps femoris of the dystrophic GRMD Mstn+/+
dogs, relative to the non-dystrophic control dogs, and the even more dramatic differential size of these muscles in the GRippet Mstn+/− dogs (also see
quantitative measurements in Additional file 2: Table S1)
Table 5 Pax7-positive cells in dystrophic and carrier dogs
Dog/muscle Genotype Pax7+ Myonuclei Percentage
Endora/CS GRMD carrier/Mstn+/+ 12 918 1.3
Endora/VL GRMD carrier/Mstn+/+ 7 1151 0.6
Esmeralda/CS GRMD carrier/Mstn+/− 8 983 0.8
Esmeralda/VL GRMD carrier/Mstn+/− 33 1173 2.8
Hagatha/CS GRMD/Mstn+/+ 68 1193 5.7
Hagatha/VL GRMD/Mstn+/+ 63 1462 4.3
Tabitha/CS GRippet/Mstn+/− 89 1651 5.4
Tabitha/VL GRippet/Mstn+/− 95 1681 5.7
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fibers (p < 0.01), while those of the GRMD dogs did not
differ (p = 0.964). These findings of muscle fiber hyper-
trophy were not seen in other muscles. In fact, in the
VL, the CSA was smaller in both dystrophic groups
(GRippets, 1560 ± 155, p < 0.01; GRMD, 1850 ± 610; p <
0.05), compared to the controls (3,196 ± 326) (Fig. 1d)
(Additional file 4: Table S3).
Hydroxyproline (HP) protein
Fibrosis is a major complicating factor of chronic myop-
athy. Studies have shown that myostatin stimulates
muscle fibroblasts and that fibrosis is reduced in the ab-
sence of myostatin [51]. Hydroxyproline content (μg
HP/mg of total muscle protein) is a biomarker of muscle
fibrosis and collagen content. Thus, we were interested
in the relative HP content of the dystrophic and control
groups. Overall HP content of GRMD dogs (26.5 ± 9.30)
was higher than controls (9.53 ± 2.56) (p < 0.05), while
that of the GRippet dogs (22.9 ± 4.79) trended towards
being higher (p = 0.053). Although HP content for indi-
vidual muscles from the dystrophic groups did not differ
significantly when compared to controls, there were
trends towards greater content in the GRippet VL (p =
0.074) and GRMD VL, CS, and LHG (all p < 0.2). Inter-
estingly, the differential between the two dystrophic
groups varied markedly among muscles, with GRippet
values being lower in the CS and LHG but higher in the
VL and LDE. None of these differences were significant
(Additional file 4: Table S3).
Myostatin mRNA and protein expression
Myostatin mRNA data from the CS and VL of these same
dogs have been reported previously [37]. Levels in the CS
of both dystrophic groups were significantly lower than
controls, while those in the VL were lower but not signifi-
cantly different. Gene expression in these muscles plus the
LDE and LHG was assessed for this current study. Levels
averaged for all four muscles were reduced to a compar-
able degree in GRippet and GRMD dogs at 8–9 months
when compared to controls but differences were not sig-
nificant. In assessing individual muscles, levels were re-
duced in the CS of GRMD (0.093 ± 0.059) and GRippet
(0.041 ± 0.026) dogs, compared to controls (1.08 ± 0.458)
(p < 0.01 for both) (Fig. 6). A less pronounced reduction
was seen in the VL of GRMD (0.306 ± 0.20) and GRippet
(0.335 ± 0.185) dogs versus controls (1.05 ± 0.388) (p <
0.05 for both) (Additional file 4: Table S3).
Similar to mRNA findings, average myostatin protein
levels (pg/mg) for the three muscles assessed were lower
in GRippet (2.94 ± 1.48) and GRMD (4.30 ± 0.98) dogs
compared to controls (7.63 ± 3.51) but differences were
not significant, nor did values differ between dystrophic
groups (p = 0.770). Levels were significantly lower in the
dystrophic versus control CS regardless of Mstn geno-
type (0.92 ± 0.73 in the GRippets and 1.63 ± 0.39 in
GRMD) vs. 7.79 ± 2.18 in the two non-dystrophic dogs)
(p < 0.05 for both). This is in keeping with the dramatic
hypertrophy seen in the CS in even Mstn+/+ GRMD dogs
[44, 56] and suggests that the hypertrophy may be more
pronounced when myostatin is further down regulated.
Fig. 6 Myostatin mRNA levels in control, GRMD, and GRippet dogs. Values were significantly reduced in the CS of GRMD and GRippet dogs, compared
to controls (p < 0.01 for both). A less pronounced reduction was seen in the VL of GRMD and GRippet dogs (p < 0.05 for both) versus controls. Values
for the LDE and LHG did not differ among the three groups. No differences were seen between GRMD and GRippet dogs. All measurements are given
in relation to HPRT values, which were normalized to 1
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Consistent with this observation, Dash, the GRippet with
the most pronounced postural changes and CS muscle
hypertrophy, also had the lowest myostatin protein levels
(0.21) by a wide margin. Values for the LDE and LGH
did not differ between the dystrophic and control dogs.
Myostatin mRNA fold change and protein levels were
correlated with MRI volumes and histopathologic
changes among the dogs (all 10 for mRNA and 8 for
protein) to help establish potential cause and effect links.
Notably, there was a significant negative correlation be-
tween CS myostatin mRNA fold change (r = −0.7297)
and protein (r = −0.7649) levels and CS percent CSA on
MRI (both p < 0.05), suggesting myostatin down regula-
tion may contribute to CS hypertrophy. A similar but
positive correlation was seen between Mstn mRNA
levels and VL volume corrected for femur length
(r = 0.680; p < 0.05), providing a further potential link
between down regulation of myostatin and VL atrophy.
With regard to histopathological findings, both myosta-
tin mRNA and protein levels in the CS correlated
negatively with the levels of degenerating fibers and CNF
(r = −0.8178, p < 0.01 for mRNA; r = −0.7617, p < 0.05 for
protein). A less pronounced effect was seen in the VL,
with mRNA levels correlating negatively with degenerat-
ing fibers (r = −0.6433, p < 0.05) and a trend occurring for
CNF (r = −0.5538, p = 0.097). These data indicate that the
exaggerated lowering of myostatin could place muscle
fibers at increased risk for injury (degenerating fibers) and
subsequent regeneration (CNF).
Activin receptor type IIB (ActRIIB)
Expression of the putative receptor for myostatin,
ActRIIB, varies among muscles in mice. For example,
the fast-twitch EDL has higher levels than the slow
twitch soleus [20]. Thus, we were interested in whether
the relative expression of ActRIIB protein among mus-
cles of dogs in this study correlated with differential
muscle size. ActRIIB protein expression normalized to
beta-actin varied markedly among the four muscles. For
Racer, the only completely normal dog, levels in the CS
(0.077 arbitrary units) were considerably lower than
those in the VL (0.299), LDE (0.408), and LHG (0.259).
In contrast, for Endora (GRMD carrier, Mstn+/+),
the CS ActRIIB level (0.190) was higher than that of
either the LDE (0.090) or LHG (0.011) but lower than
the VL (0.391). Thus, based on these limited data
from the two non-dystrophic, Mstn+/+ dogs, there was
no clear pattern of differential ActRIIB expression
among the four muscles to account for the pattern of
muscle atrophy/hypertrophy protein (Additional file 4:
Table S3 and Fig. 7).
ActRIIB levels have not been assessed previously in
GRMD dogs. Interestingly, levels for all muscles of the
combined dystrophic dogs (0.98 ± 0.42) were higher
compared to average overall values for Racer and
Endora, the two non-dystrophic dogs with wild-type
myostatin (0.22 ± 0.06) (p < 0.01). Moreover, ActRIIB
levels in individual muscles were higher in dystrophic
dogs (CS, p < 0.01; VL and LDE, p < 0.05) in all but the
LHG (p = 0.585). However, neither overall mean (GRip-
pet 0.92 ± 0.52; GRMD 1.06 ± 0.32) (p = 0.903) nor indi-
vidual muscle ActRIIB expression differed between the
Mstn+/+ and Mstn+/−dystrophic groups.
The level of feedback between myostatin and ActRIIB,
or other growth factors and receptors, could differ among
muscles, leading to variable atrophy or hypertrophy. We
correlated levels of ActRIIB protein with myostatin mRNA
and protein to further establish a potential relationship.
We were particularly interested in the CS muscle,
given its marked hypertrophy. For all dogs taken to-
gether, levels of CS ActRIIB trended to correlate
negatively with those of myostatin mRNA (r = −0.726;
p = 0.108) and protein (r = −0.6739; p = 0.142). This
would be in keeping with an expected physiologic re-
lationship between the two, with ActRIIB levels in-
creasing as myostatin levels decline. The degree of
correlation between myostatin mRNA and ActRIIB
levels was assessed in the dystrophic groups alone to
gain further insight into potential disease associations.
No correlations were seen.
Fig. 7 Western blots of ActRIIB levels normalized to β-actin. Blots from
muscles of the two myostatin wild-type (Racer and Endora), three
GRMD (Flash, Samantha, and Hagatha), and four GRippet (Dash, Abner,
Derwood, and Tabitha) dogs are shown. Levels are upregulated in the
dystrophic dogs compared to controls, but there is no consistent
difference among individual muscles or between the GRMD and
GRippet dogs. Levels are expressed in arbitrary units
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Discussion
Development of myostatin inhibitors for muscle-wasting
disorders is based on the assumption that enhanced
muscle regeneration will improve muscle function. Be-
cause mdx mice, which lack myostatin [13, 14] or in
which myostatin is blocked [15] are less severely af-
fected, we hypothesized that the relative genetic loss of
myostatin would improve signs in dystrophic dogs. In-
terpretation of data in this study is compromised by the
small group sizes and the inherent phenotypic variation
seen in GRMD dogs. With that said, phenotypic features
of GRMD dogs heterozygous for myostatin (GRippets)
and their GRMD littermates were similar. Thus, we were
unable to demonstrate a beneficial effect of reduced
myostatin in GRMD dogs. In fact, when compared to
their GRMD dystrophic littermates, GRippets actually
had more severe postural changes, evidenced by an ex-
aggerated plantigrade stance, shifting of the pelvic limbs
forward, and more restricted hip joint flexion. Strikingly,
the relative absence of myostatin in the GRippets exag-
gerated pre-existing trends for either muscle atrophy or
hypertrophy on MRI, most notably in the quadriceps
and sartorius muscles, as shown by the progressive in-
crease of the CS to VL volume ratio of the non-
dystrophic controls (0.24 ± 0.06), to the GRMD dogs
(0.48 ± 0.04), to the GRippets (0.86 ± 0.10). This differen-
tial pattern of muscle atrophy/hypertrophy appeared to
have functional consequences, in that CS and VL vol-
umes correlated, in opposite directions, with maximal
hip flexion angle.
We have previously demonstrated unequal disease ef-
fects on TTJ flexors and extensors in natural history and
preclinical studies in GRMD dogs [36, 42] and shown
that proportional weakness of TTJ extensors or in-
creased strength of flexors exaggerates TTJ joint flexor
contractures [38]. Moreover, the degree of CS hyper-
trophy in GRMD correlates negatively with the TTJ joint
angle [44], suggesting that this muscle could play a role
analogous to iliotibial band tightening in DMD [57]. Dif-
ferential muscle involvement also plays a role in the
DMD disease course. Unbalanced forces acting on a
joint, due to either disproportionate muscle weakening
or shortening, lead to abnormal positioning. Several
studies have assessed the proportional strength of joint
agonist and antagonist muscles in DMD, with most con-
cluding that muscle imbalance contributes to contrac-
tures [58–62]. Those noting a relationship identified a
strong negative correlation between extensor muscle
weakness and flexor contracture severity in DMD. As
opposing extensor muscles weakened, flexor contrac-
tures worsened. To our knowledge, such contractures
and postural changes are not seen in bully whippet dogs
(Mstn−/−) despite their gross muscle enlargement. In-
stead, a single bully whippet included in the original
study was judged to run faster than myostatin wild-type
dogs [12]. This suggests that contractures are only pre-
cipitated when myostatin down regulation is coupled
with the dystrophic state.
Key questions arising from our study relate to (1) why
relative loss of myostatin would cause differential muscle
effects that exaggerate the GRMD phenotype and (2)
whether this untoward effect could potentially extend to
postnatal treatment of humans with muscle-wasting dis-
orders. Treatments directed at inhibiting or blocking
myostatin are driven by a belief that myostatin is in-
nately limiting the muscle regenerative response. Im-
portantly, in considering potential therapies for DMD,
one must take into account homeostatic compensatory
mechanisms that are already in play. In cases of muscle
loss, the body should naturally suppress myostatin ex-
pression to promote muscle regeneration. Indeed, micro-
array gene expression profiling in DMD [63], the mdx
mouse [64], and GRMD dog [56] has shown that myos-
tatin is down regulated in dystrophic muscle independ-
ent of modulating treatments. Consistent with findings
reported here, the degree of myostatin mRNA down
regulation in GRMD dogs also has been shown previ-
ously to vary among muscles, with levels being dramatic-
ally reduced in the CS, a hip flexor prone to hypertrophy
(44, 56), and less so or not at all in selected extensor
muscles [56]. Not surprisingly, myostatin mRNA and
protein levels in the CS of the GRippet dogs of our study
were also markedly reduced when measured at 8–9
months of age. Interestingly, at this relatively late age,
the GRippet levels were not significantly lower than
those in their myostatin wild-type GRMD littermates.
Had levels been measured earlier, particularly in advance
of the rapid period of disease progression beginning at
3 months [36], we may have been able to distinguish a
difference between GRMD and GRippet dogs. With this
said, correlations between myostatin mRNA and protein
levels with phenotypic features such as CS muscle vol-
ume on MRI and the degree of degenerating and regen-
erating fibers in both the CS and VL still suggested that
the myostatin expression could contribute to variable
muscle effects and the overall disease phenotype
The differential response of murine muscles to loss of
myostatin is associated with varying levels of the myosta-
tin receptor, ActRIIB [20]. In comparing ActRIIB levels
among the three groups of dogs in our study, dystrophic
dogs taken together had significantly higher levels than
non-dystrophic controls, suggesting a feedback mechan-
ism whereby ActRIIB levels increase secondary to lower-
ing of myostatin. Similarly, when all dogs were assessed
collectively, myostatin mRNA and protein levels tended
to correlate negatively with ActRIIB expression in the
CS muscle and, to a lesser extent, the VL. This would be
in keeping with an expected physiologic relationship
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between the two, with ActRIIB levels increasing as
myostatin levels decline. On the other hand, when the
dystrophic groups were assessed alone, no correlation
was seen. This likely is simply a function of small group
sizes and the stringency of the FDR statistical method
but could point to dysregulation in dystrophic muscle.
Myostatin favors differentiation towards slow versus
fast glycolytic fibers, due apparently to positive and
negative regulation of MEF2 and MyoD, respectively
[65]. Consistent with this effect, cattle lacking Mstn
[66] and Mstn-null mice [67] have increased numbers
of fast glycolytic fibers. Therefore, in principle, fiber
type distribution could influence effects of myostatin
loss or blockade. Muscles with a predominantly fast
glycolytic fiber type distribution could be more sensi-
tive to the absence of myostatin and display greater
hypertrophy. While most murine muscles respond
similarly to genetic depletion of myostatin [5], the
slow twitch soleus undergoes less pronounced hyper-
trophy than the fast-twitch EDL [20, 22, 24]. Based
on the fast/slow fiber type distribution of canine mus-
cles, the CS (49:51), VL (57:43), and LHG (50:50) are
mixed muscles, while the LDE (71:29) is predomin-
antly fast-twitch [68]. Independent of myostatin sta-
tus, the GRMD LDE undergoes dramatic atrophy, the
VL and LHG are moderately atrophied, and the CS is
markedly hypertrophied [44, 56]. Therefore, fiber type
distribution, alone, does not appear to be a major fac-
tor in GRMD muscle atrophy/hypertrophy.
With regard to the second question posed above on
the potential for our findings to translate to humans,
it is not clear whether deleterious effects of genetic
loss of myostatin will extend to postnatal treatments.
During development, myostatin down regulates myo-
genic regulators such as MyoD to inhibit proliferation
and differentiation of myoblasts [5, 69]. Genetic loss
of myostatin in the mouse accelerates both primary
(embryo) and secondary (fetal) myogenesis, with an
increase in myofiber numbers (hyperplasia) and size
(hypertrophy) [70]. Myostatin-null mice have attained
87 % of their final adult number of myofibers by em-
bryonic day 18.5 (near term) compared to only 73 %
of wild-type mice [70]. Further postnatal muscle en-
largement relies more on an increase in protein syn-
thesis rather than incorporation of more nuclei [70].
Thus, one would logically suspect that effects of gen-
etic versus postnatal loss or inhibition of myostatin
would differ. However, the postural abnormalities seen
in the GRippet dogs of our study did not become ap-
parent until around 3 months of age. Accordingly,
while the basis for differential muscle involvement
may have been established in the embryo, phenotypic
effects were not seen until after birth. Further, a pre-
vious study investigated the effect of postnatal
stimulation of muscle growth in four GRMD dogs for
4 months beginning at 2.5 months of age. Results of
this study were presented at the 16th International
Congress of the World Muscle Society in 2011 [71]
but have not been published. This study used treat-
ment with anti-ActRIIB antibody, an inhibitor of mul-
tiple BMP ligands including myostatin, to increase
muscle growth. Overall muscle mass did not increase
in treated dogs compared to GRMD controls. In
keeping with our GRippet findings, several indices of
motor function declined in treated dogs (Blot S, per-
sonal communication, 2015). While these findings are
consistent with those of the GRippets, they may not
have been specific to the effects of myostatin inhib-
ition because a non-selective inhibitor was used.
We have previously shown that myostatin blockade
with an AAV8-myostatin propeptide construct admin-
istered via regional limb delivery in 3-month-old nor-
mal dogs leads to muscle enlargement [31]. As with
the GRippets reported here, the effects were not uni-
form among muscles. In particular, the treated VL
showed no increase in size, even though transgene
levels were comparable to muscles that showed a
treatment effect. In a separate study, a group of
GRMD dogs were treated systemically with AAV8-
myostatin dominant negative propeptide at 10 months
of age and followed for 13 months with MRI and at
necropsy to determine effects on distal pelvic limb
muscle size [32]. All treated GRMD muscles in-
creased in size but the degree varied, ranging from
27 % in the LDE to 49 % in the cranial tibialis. Not-
ably, none of the muscles in either of these studies
decreased in size. This contrasts with our findings
in the GRIppets, in which the relative absence of
myostatin exaggerated pre-existing trends for either
muscle atrophy or hypertrophy. Exaggeration of
muscle atrophy, as with the quadriceps, is particu-
larly puzzling and could have considerable potential
clinical significance.
Treatments directed at inhibiting myostatin to in-
crease the regenerative response of diseased muscle have
been postulated to potentially exhaust satellite cell repli-
cative capacity [24]. Previous studies with dystrophic
mouse models and genetic deletion or postnatal inhib-
ition of myostatin are not adequate to address the ques-
tion of satellite cell senescence since mice have
considerably longer telomeres [72] and proportionally
higher telomerase activity than humans [73]. Like
humans, dogs have relatively short telomeres and low
telomerase activity [74, 75]. The GRippet is thus a good
model to evaluate satellite cell populations in dystrophic
muscle with chronic reduction in myostatin. Despite ac-
tive degeneration and regeneration in GRippet muscles,
satellite cells were the same proportion (approximately
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5–6 %) of myonuclei as in GRMD muscles and did not
show evidence of exhaustion.
Conclusions
Myostatin mRNA and protein levels were down regu-
lated in GRMD dogs independent of myostatin status,
suggesting an inherent feedback mechanism intended to
promote muscle regeneration. The relative absence of
myostatin in the GRippets exaggerated pre-existing
trends for either muscle atrophy or hypertrophy on
MRI. This differential pattern of muscle atrophy/hyper-
trophy appeared to have functional consequences, in
that phenotypic features of the GRippets were, if any-
thing, more severe than GRMD dogs with wild-type
myostatin. Results from these GRippet dogs suggest that
dystrophic muscles may be differentially affected by in
utero myostatin loss. While data derived from dystrophic
dogs lacking myostatin from inception will not necessar-
ily extrapolate to postnatal treatments, this study rein-
forces the complexity of factors regulating muscle
function and further emphasizes that murine models of
muscular dystrophy may behave very differently than
large animals such as dogs and humans. Although the
lack of satellite cell exhaustion in GRippets is reassuring
for future human experience with myostatin inhibitors,
the muscle imbalance and severity of contractures re-
quires continued careful evaluation. These findings may
serve to inform future clinical trials of postnatal myosta-
tin inhibition.
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Additional file 1: Figure S1. Histograms depicting percent cross-
sectional area contributed by each muscle on MRI at midthigh of control,
GRMD, and GRippet dogs. Pre-existing atrophy or hypertrophy in GRMD
muscles is generally more exaggerated in the GRippets. (TIF 664 kb)
Additional file 2: Table S1. MRI volumes in non-dystrophic control,
GRMD (Mstn+/+), and GRippet (Mstn+/−) Dogs (Mean ± SD). (DOCX 954 kb)
Additional file 3: Table S2. T2 mapping values (Mean ± SD) in non-
dystrophic control, GRMD (Mstn+/+), and GRippet (Mstn+/−) Dogs
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molecular findings in non-dystrophic control, GRMD (Mstn+/+), and GRip-
pet (Mstn+/−) dogs. (DOCX 403 kb)
Additional file 5: Figure S2. Pax7-positive cells in Mstn+/+ and Mstn+/−
GRMD/GRippet and GRMD-carrier dogs. Laminin (A), Pax7 (B), DAPI (C), and
merged (D) staining are seen. Satellite cells were defined as Pax7+ nuclei
within the laminin + basal lamina (also see data in Additional file 4:
Table S3). (TIF 915 kb)
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